Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

Digital and AI

 

Sword Health acquires Germany’s Kaia Health

Sword Health, a US-based AI care company focused on digital treatment for muscle, joint and pelvic health conditions, is acquiring Germany’s Kaia Health in a deal valued at $285 million.

Interview: George Tomeski, Helfie AI

Helfie AI is an Australian start-up that is building what its founder, George Tomeski, describes as “a whole new operating system for human health”. This is not simply hyperbole or PR-speak. What Helfie is building is indeed groundbreaking.

Interview: Neil Daly, Skin Analytics

Skin Analytics is a UK company that has developed an AI-based software tool to analyse whether patients with skin lesions have cancer. In a conversation with HBI, the company’s CEO, Neil Daly, explained how AI tools need to be able to make accurate clinical decisions autonomously, without human input, in order to provide an efficiency benefit to the healthcare system.

UK care sector draws strong interest from global private equity

2025 was a busy year for the care sector, with lots of M&A deals either happening, planned, or being considered. Activity has risen sharply and the market is currently at a high point. HBI spoke with Amar Shah, Partner, and Vikas Sharma, Director, both in Healthcare and Life Sciences M&A at Deloitte UK, about trends in the UK social care market, including investment flows, valuations, staffing, technology and expectations for 2026.

HBI’s Digital Health Special Report 2025

HBI's first ever Special Report on digital health features analysis and commentary from various experts on the current state of play in digital health, and where the market might be headed, as well as in depth case study interviews with eight different digital health companies, each showcasing a different aspect to healthcare's digital revolution: HealthHero, Kry/Livi, Arts en Zorg, Health Navigator (HN), Helfie AI, Clue, Hellobetter and Flow Neuroscience.

Thermo Fisher buys clinical software company Clario for $9bn

Thermo Fisher, a US life sciences and clinical research company listed on the New York Stock Exchange, has acquired Clario, a US company that provides software for clinical trials, from private equity firms Nordic Capital and Astorg Partners, for around $9 billion.

Find Us